In the landscape of infectious diseases, human coronaviruses such as SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2 pose significant threats, characterized by severe respiratory illnesses and notable resistance to conventional treatments due to their rapid evolution and the emergence of diverse variants, particularly within SARS‐CoV‐2. This study investigated the development of broad‐spectrum coronavirus vaccines using heterodimeric RBD‐Fc proteins engineered through the “Knob‐into‐Hole“ technique. We constructed various recombinant proteins incorporating the receptor‐binding domains (RBDs) of different coronaviruses. Heterodimers combining RBDs from SARS‐CoV‐2 with those of SARS‐CoV or MERS‐CoV elicited superior neutralizing responses compared to homodimeric proteins in murine models. Additionally, heterotetrameric proteins, specifically D614G_Delta/BA.1_XBB.1.5‐RBD and MERS_D614G/BA.1_XBB.1.5‐RBD, elicited remarkable breadth and potency in neutralizing all known SARS‐CoV‐2 variants, SARS‐CoV, related sarbecoviruses like GD‐Pangolin and WIV1, and even MERS‐CoV pseudoviruses. Furthermore, these heterotetrameric proteins also demonstrated enhanced cellular immune responses. These findings underscore the potential of recombinant hetero proteins as a universal vaccine strategy against current and future coronavirus threats.